Article Details
Retrieved on: 2024-12-02 22:52:23
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the American Diabetes Association's warning against compounded versions of drugs like semaglutide and tirzepatide, used for obesity and diabetes, due to safety concerns. This relates to issues of drug quality, biopharma regulation, and demand challenges faced by companies like Novo Nordisk and Eli Lilly.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here